Caldera Therapeutics, a clinical stage company focused on developing novel treatments for inflammatory and immunologic diseases, has successfully raised $112.5 million in new investment capital. This significant funding round is poised to accelerate the clinical development of its lead therapeutic candidate and support the company's broader strategic growth initiatives.
The company is developing CLD-423, a first-in-class bispecific antibody. CLD-423 targets the clinically validated IL-23p19 and TL1A pathways, designed for the treatment of inflammatory bowel disease (IBD) and other related immunologic and inflammatory conditions. Caldera Therapeutics operates as a clinical stage entity, progressing its innovative pipeline.
This substantial capital infusion underscores investor confidence in Caldera Therapeutics' scientific approach and its potential to address significant unmet medical needs. The funding round saw participation from leading biotech investors including Atlas Venture, LAV, venBio, Omega Funds, Wellington Management, and Janus Henderson Investors. The company has also assembled a senior leadership team with extensive experience in IBD therapeutics discovery and development, and a proven track record in building successful biotechnology companies.
Caldera Therapeutics plans to deploy the newly secured funds primarily to advance CLD-423 through its critical clinical development stages, including ongoing trials and future studies. The capital will also support further research and development efforts, potentially enabling the expansion of its pipeline of novel therapies. This investment positions Caldera Therapeutics for continued progress in bringing its innovative treatments closer to patients, reinforcing its commitment to addressing complex inflammatory and immunologic diseases and achieving its long-term growth objectives.
.png&w=3840&q=75)
